Against the backdrop of the ASCO 2010 theme “advancing quality through innovation”,
Quintiles brought together an esteemed faculty of leading international experts in oncology drug development in a unique ancillary event, Mapping the Future in Oncology Drug Development. Dr. Paul Bunn, Jr., M.D., Past-President of the American Society of Clinical Oncology (ASCO) 2002–2003, chaired the event, which included plenary presentations and stimulating discussions around key issues of the moment in oncology drug development.

In this paper, Harish Dave and Eric Groves review the insights from the ancillary event and discuss potential solutions to improve the productivity of oncology drug development and ultimately patient care; with thanks to our distinguished panel for the insights that they provided (for the full program see page 20). Owing to the wide scope of the subject, market-access strategies are not reviewed.